Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan

doi:10.7717/peerj.9998

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24938

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24938

Title:	Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
Authors:	Chen, JF;Peng, YS;Chen, CS;Tseng, CH;Chen, PC;Lee, TI;Lu, YC;Yang, YS;Lin, CL;Hung, YJ;Chen, ST;Lu, CH;Yang, CY;Chen, CC;Lee, CC;Hsiao, PJ;Jiang, JY;Tu, ST
Keywords:	Dapagliflozin;HbA1c;SGLT2 inhibitors;Type 2 diabetes mellitus;Real-world evidence
Date:	2020
Issue Date:	2022-08-09T08:10:30Z (UTC)
Publisher:	PEERJ INC
ISSN:	2167-8359
Abstract:	Aims/Introduction. To investigate the clinical outcomes of patients with type 2 diabetes mellitus (T2DM) who initiated dapagliflozin in real-world practice in Taiwan. Materials and Methods. In this multicenter retrospective study, adult patients with T2DM who initiated dapagliflozin after May 1st 2016 either as add-on or switch therapy were included. Changes in clinical and laboratory parameters were evaluated at 3 and 6 months. Baseline factors associated with dapagliflozin response in glycated hemoglobin (HbAlc) were analyzed by univariate and multivariate logistic regression. Results. A total of 1,960 patients were eligible. At 6 months, significant changes were observed: HbA1c by -0.73% (95% confidence interval [CI] -0.80, -0.67), body weight was -1.61 kg (95% CI -1.79, -1.42), and systolic/diastolic blood pressure by -3.6/-1.4 mmHg. Add-on dapagliflozin showed significantly greater HbA1c reduction (-0.82%) than switched therapy (-0.66%) (p = 0.002). The proportion of patients achieving HbA1c <7% target increased from 6% at baseline to 19% at Month 6. Almost 80% of patients experienced at least 1% reduction in HbA1c, and 65% of patients showed both weight loss and reduction in HbA1c. Around 37% of patients had at least 3% weight loss. Multivariate logistic regression analysis indicated patients with higher baseline HbA1c and those who initiated dapagliflozin as add-on therapy were associated with a greater reduction in HbA1c. Conclusions. In this real-world study with the highest patient number of Chinese population to date, the use of dapagliflozin was associated with significant improvement in glycemic control, body weight, and blood pressure in patients with T2DM. Initiating dapagliflozin as add-on therapy showed better glycemic control than as switch therapy.
URI:	http://dx.doi.org/10.7717/peerj.9998 https://www.webofscience.com/wos/woscc/full-record/WOS:000589900500014 https://ir.csmu.edu.tw:8080/handle/310902500/24938
Relation:	PEERJ ,2020 ,v8
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	277	View/Open

Loading...